• NuCana highlighted NUC-7738 as its lead oncology program, positioning it to improve responses to PD-(L)1 inhibitors in resistant tumors.
• NuTide:701 monotherapy data showed a 41% disease control rate in efficacy-evaluable patients, with no Grade 4 toxicities reported.
• Combination dosing in melanoma paired NUC-7738 with pembrolizumab, with tumor reductions of 55% and 32% cited in heavily pretreated patients.
• Cash and cash equivalents were about USD 28.4 million as of March 31, 2026, with runway projected into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.